Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in east asian patients with advanced non-small cell lung cancer: Results of an exploratory subgroup analysis of a phase III trial

Journal of Thoracic Oncology

Volumn 5, Issue 5, 2010, Pages 688-695

  Yang, Chih Hsin ^a   Simms, Lorinda ^b   Park, Keunchil ^c   Lee, Jin Soo ^d   Scagliotti, Giorgio ^e   Orlando, Mauro ^f  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b ELI LILLY AND COMPANY   (United States)

^c Sungkyunkwan University   (South Korea)

^d National Cancer Center   (South Korea)

^e UNIVERSITY OF TURIN   (Italy)

^f Edificio Panamericana Plaza   (Argentina)

Author keywords

Asian; Cisplatin; Gemcitabine; Non small cell lung cancer; Pemetrexed

Indexed keywords

CISPLATIN; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED;

ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOKALEMIA; KOREA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; POST HOC ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RACE; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SIDE EFFECT; SMOKING; TAIWAN; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 77951876335     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d1273d     Document Type: Article

References (18)

1. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
2. Stinchcombe TE, Socinski MA. Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 2009;6:233-241.
3. Hirsch FR, Spreafico A, Novello S, et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 2008;3:1468-1481.
4. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253-263.
5. Chang AY. The role of gefitinib in the management of Asian patients with non-small cell lung cancer. Expert Opin Investig Drugs 2008;17: 401-411.
6. Blackhall F, Ranson M, Thatcher N. Where next for gefitinib in patients with lung cancer? Lancet Oncol 2006;7:499-507.
7. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
8. Tamura T, Nishiwaki Y, Watanabe K, et al. Evaluation of the efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non-small cell lung cancer (NSCLC); integrated analysis of two Japanese phase II studies. J Thorac Oncol 2007;2(suppl):S742.
9. Esteban E, Casillas M, Cassinello A. Pemetrexed in first-line treatment of non-small cell lung cancer. Cancer Treat Rev 2009;35:364-373.
10. Kubota K, Niho S, Enatsu S, et al. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer. Review of results from an open-label randomized phase II study. J Thorac Oncol 2009;4:1530-1536.
11. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
12. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
13. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
14. Sekine I, Nokihara H, Yamamoto N, et al. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer 2006;53:157-164.
15. Sekine I, Yamamoto N, Nishio K, et al. Emerging ethnic differences in lung cancer therapy. Br J Cancer 2008;99:1757-1762.
16. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107: 1589-1596.
17. Rudin CM, Avila-Tang E, Harris CC, et al. Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res 2009;15:5646-5661.
18. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009;27:3540-3546.